Open AccessOffice and Ambulatory Blood Pressure–Lowering Effects of Combination Valsartan/Hydrochlorothiazide vs Hydrochlorothiazide‐Based Therapy in Obese, Hypertensive Patients
Author(s) -
Raij Leopoldo,
Egan Brent M.,
Zappe Dion H.,
Purkayastha Das,
Samuel Rita,
Sowers James R.
Publication year - 2011
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1751-7176.2011.00499.x
Subject(s) - hydrochlorothiazide , medicine , valsartan , amlodipine , blood pressure , ambulatory blood pressure , ambulatory , urology , population , diastole , cardiology , environmental health
J Clin Hypertens (Greenwich) . 2011;13:731–738. ©2011 Wiley Periodicals, Inc. The authors evaluated the blood pressure (BP)–lowering effects of combination valsartan/hydrochlorothiazide (HCTZ) vs amlodipine/HCTZ in a 16‐week, double‐blind, randomized, forced‐titration study and ambulatory BP monitoring (ABPM) substudy involving centrally obese hypertensive patients 40 years and older. Patients were started on valsartan/HCTZ 160/12.5 mg or HCTZ 12.5 mg monotherapy, force‐titrated at week 4 to valsartan/HCTZ 320/25 mg and HCTZ 25 mg, respectively. The HCTZ group initiated amlodipine 5 mg at week 8 and 10 mg at week 12. A subset of patients had 24‐hour ABPM at baseline and weeks 8 and 16. At week 16 in the intent‐to‐treat population (n=401), valsartan/HCTZ and amlodipine/HCTZ lowered office systolic BP (−30.6 vs −28.3 mm Hg; P =.14). In the ABPM subgroup (n=111), valsartan/HCTZ was more effective than amlodipine/HCTZ in reducing 24‐hour systolic BP (−20.6 vs −14.5 mm Hg; P =.011). In obese hypertensive patients, valsartan/HCTZ reduced office BP similar to amlodipine/HCTZ but lowered 24‐hour systolic BP more. J Clin Hypertens (Greenwich). ****;**:**–**.